www.squeezetrigger.com is monitoring AVANIR PHARMACEUTICALS INC-A (NASDAQ:AVNR) in real time and just received an alert that AVNR is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock.

There are 30890200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $3.51.

From August 2009 to May 2011, an aggregate amount of 405655689 shares of AVNR have been shorted for a total dollar value of $1216967067.

The AVNR SqueezeTrigger price of $3.51 is the volume weighted average price that all shorts are short in shares of AVNR.

There is still approximately $110,278,014 of potential short covering in shares of AVNR.

My Comment: this stock is 80% institutional owned so not many shares availiable, first shorting fund that blinks starts the run-up...........high beta, high drama, price target $6.00

Sales out at the beginning of August, got an upgrade today from:

Canaccord Genuity Reiterates a 'Buy' on Avanir Pharmaceuticals (AVNR); FQ3/11 Preview: Nuedexta Sales on Track, Beating 'New Normal'

July 7, 2011 12:59 PM EDT

Canaccord Genuity reiterates a 'Buy' on Avanir Pharmaceuticals (NASDAQ: AVNR), PT $6.

Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on Nuedexta ultimate commercial potential despite slow launch. Nuedexta is AVNR’s drug for pseudobulbar affect, emotional lability seen in neurodegenerative diseases like ALS, MS, and stroke. Launch has been slower than first predicted, but we anticipate peak annual sales of $350M US, $300M EU. Our $6 target is based on a sum-of-the-parts analysis."

"We see FQ3/11 Nuedexta sales on track for $1.9M, beating our previously revised $1.5M estimate. We think consensus sales are very close to our estimate when consensus revenue ($2.5M) is adjusted for royalties. Wolters Kluwer monthly April and May sales totalled $1.1M. Assuming a 20% growth rate from May, June sales may reach $0.8M, bringing FQ3 total sales to $1.9M. Monthly sales grew 57% in May, 22% in April. June sales would have to fall 50% from May to miss our former $1.5M FQ3 forecast."